

Patrick W Mellors

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8678079/publications.pdf>

Version: 2024-02-01

10
papers

73
citations

1937685
4
h-index

1474206
9
g-index

11
all docs

11
docs citations

11
times ranked

196
citing authors

#	ARTICLE	IF	CITATIONS
1	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50.	6.2	25
2	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2020, 4, 2236-2244.	5.2	20
3	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 889-894.	4.1	14
4	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2022, 97, 209-215.	4.1	5
5	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2960-2967.	1.3	4
6	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020, 136, 48-49.	1.4	2
7	Belantamab mafodotin detection by MASS-FIX and immunofixation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e430-e433.	2.3	1
8	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 1902-1902.	1.4	1
9	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 4396-4396.	1.4	0
10	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , 2020, 136, 44-45.	1.4	0